1
|
Hindi SM, Vittinghoff E, Schafer AL, Silverman S, Bauer DC. Commercial Laboratory Reproducibility of Serum CTX in Clinical Practice. JBMR Plus 2019; 3:e10225. [PMID: 31687653 PMCID: PMC6820459 DOI: 10.1002/jbm4.10225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2019] [Revised: 07/01/2019] [Accepted: 07/22/2019] [Indexed: 11/12/2022] Open
Abstract
In 2011, the International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine selected serum collagen type‐I crosslinked C‐peptide (s‐CTX) as the reference standard for bone resorption. This study aimed to determine the within and between laboratory reproducibility for s‐CTX assays. To create standardized pools, serum was collected from 10 premenopausal and 10 postmenopausal women. Premenopausal sera were pooled to approximate a population with normal bone turnover; postmenopausal sera were pooled to approximate a population with high bone turnover; and a third pool was created from an equal proportion of the pre‐ and postmenopausal pools. Multiple identical aliquots from each pool were created and frozen; all were labeled as routine clinical specimens. To evaluate longitudinal laboratory reproducibility, an identical aliquot from each of the three pools was sent to four US commercial laboratories on five dates over a 6‐month period. To evaluate within‐run reproducibility, each lab received five identical aliquots from each pool on the fifth date. Three labs (Mayo, ARUP, and Quest) used the Roche Diagnostics Elecsys assay, and one (Esoterix/LabCorp) used the IDS‐iSYS assay. Reproducibility was assessed using the coefficient of variation (CV) with 95% confidence intervals (CIs). Labs were unaware of the investigation. Across labs, mean s‐CTX values were 423, 533, and 480 pg/mL for the premenopausal, postmenopausal, and mixed pools, respectively, but the means differed between labs (p < 0.001). The premenopausal pool longitudinal CVs ranged from 5.0% to 14.9%; the postmenopausal pool CVs ranged from 3.4% to 19.3%; and the mixed pool CVs ranged from 3.3% to 16.0%. The longitudinal reproducibility for Esoterix/LabCorp was higher (CV 13.9%; 95% CI, 10.1% to 22.2%) than for the other labs. Within‐run CVs were also higher for Esoterix/LabCorp (CV 8.6%; 95% CI, 6.3% to 13.6%) compared with the other labs (CVs 2.1% to 6.2%). In conclusion, the reproducibility of s‐CTX varied across US commercial labs, and was poorer for Esoterix/LabCorp, which used the IDS assay, compared with the other three labs, which used the Roche assay. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Sahar M Hindi
- Division of Endocrinology Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi Abu Dhabi United Arab Emirates
| | - Eric Vittinghoff
- Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco CA USA
| | - Anne L Schafer
- Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco CA USA.,Medical Service Endocrinology and Metabolism Section, San Francisco Veterans Affairs Health Care System San Francisco CA USA.,Department of Medicine, Division of Endocrinology and Metabolism University of California, San Francisco San Francisco CA USA
| | - Stuart Silverman
- Cedars Sinai Medical Center UCLA School of Medicine Los Angeles CA USA
| | - Douglas C Bauer
- Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco CA USA.,Department of Medicine, Division of General Internal Medicine University of California, San Francisco San Francisco CA USA
| |
Collapse
|
2
|
Hindi SM, Wang Y, Jones KD, Nussbaum JC, Chang Y, Masharani U, Bikle D, Shoback DM, Hsiao EC. A Case of Hypercalcemia and Overexpression of CYP27B1 in Skeletal Muscle Lesions in a Patient with HIV Infection After Cosmetic Injections with Polymethylmethacrylate (PMMA) for Wasting. Calcif Tissue Int 2015; 97:634-9. [PMID: 26253396 PMCID: PMC4861400 DOI: 10.1007/s00223-015-0048-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 07/29/2015] [Indexed: 10/23/2022]
Abstract
Foreign body-induced granuloma is an uncommon yet clinically significant cause of hypercalcemia. The molecular mechanisms are uncertain, although extrarenal calcitriol production has been proposed. We describe severe hypercalcemia associated with increased levels of plasma calcitriol in a patient with HIV and local granulomatous reaction 5 years after injection of polymethylmethacrylate (PMMA) as dermal filler for cosmetic body sculpting. Extensive evaluation revealed no identifiable cause of increased calcitriol levels. Nuclear imaging was remarkable for diffuse uptake in the subcutaneous tissues of the buttocks. Subsequent muscle biopsy and immunohistochemical staining showed strong local expression of CYP27B1 within histiocytes surrounding globules of PMMA. This case highlights an unfortunate complication of dermal fillers and shows that inflammatory cells can express high levels of CYP27B1 even without frank granulomas. The growing trend of body contour enhancement using injectable fillers should raise suspicion for this cause of hypercalcemia in clinical practice. Patients with HIV who receive this treatment for lipodystrophy or other cosmetic purposes may have increased susceptibility to hypercalcemia in the setting of underlying chronic inflammation. This may be a concern when changing anti-retroviral therapy, since alterations in levels of HIV viremia may initiate or contribute to worsening hypercalcemia.
Collapse
Affiliation(s)
- Sahar M Hindi
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, HSE901G, UCSF Box 0794, San Francisco, CA, 94143-0794, USA
| | - Yongmei Wang
- Endocrine Research Unit, Department of Veterans Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Kirk D Jones
- Department of Pathology, University of California, San Francisco, San Francisco, CA, USA
| | - Jesse C Nussbaum
- Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Yongen Chang
- Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Umesh Masharani
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, HSE901G, UCSF Box 0794, San Francisco, CA, 94143-0794, USA
| | - Daniel Bikle
- Endocrine Research Unit, Department of Veterans Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Dolores M Shoback
- Endocrine Research Unit, Department of Veterans Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Edward C Hsiao
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, HSE901G, UCSF Box 0794, San Francisco, CA, 94143-0794, USA.
- Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
| |
Collapse
|